Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Myelodysplastic-Myeloproliferative Diseases 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Biphenotypic, Acute 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

decitabine and cedazuridine drug combination 1Injections 1Decitabine 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Accelerated Phase Myeloproliferative Neoplasm × decitabine and cedazuridine drug combination × Clear all
NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
27 enrolled
Myeloid

Accelerated Phase Myeloproliferative Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡